Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet

被引：83

作者：

Hayami, Tomohide ^{[1
]}

Kato, Yoshiro ^{[1
]}

Kamiya, Hideki ^{[1
]}

Kondo, Masaki ^{[1
]}

Naito, Ena ^{[1
]}

Sugiura, Yukako ^{[1
]}

Kojima, Chika ^{[1
]}

Sato, Sami ^{[1
]}

Yamada, Yuichiro ^{[1
]}

Kasagi, Rina ^{[1
]}

Ando, Toshihito ^{[1
]}

Noda, Saeko ^{[1
]}

Nakai, Hiromi ^{[1
]}

Takada, Eriko ^{[1
]}

Asano, Emi ^{[1
]}

Motegi, Mikio ^{[1
]}

Watarai, Atsuko ^{[2
]}

Kato, Koichi ^{[3
]}

Nakamura, Jiro ^{[1
]}

机构：

[1] Aichi Med Univ, Sch Med, Dept Internal Med, Div Diabet, Nagakute, Aichi 48011, Japan

[2] Chubu Rosai Hosp, Ctr Prevent Med, Nagoya, Aichi, Japan

[3] Aichi Gakuin Univ, Sch Pharm, Lab Med, Nagoya, Aichi 464, Japan

来源：

JOURNAL OF DIABETES INVESTIGATION | 2015年 / 6卷 / 05期

关键词：

Ketoacidosis; Low-carbohydrate diet; Sodium-glucose cotransporter2 inhibitor; INSULIN SENSITIVITY; DAPAGLIFLOZIN;

D O I：

10.1111/jdi.12330

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We present a case of a 32-year-old diabetic woman with Prader-Willi syndrome who developed severe ketoacidosis caused by a sodium-glucose cotransporter2 (SGLT2) inhibitor, a novel class of antihyperglycemic agents, during a strict low-carbohydrate diet. At admission, a serum glucose level of 191mg/dL was relatively low, though laboratory evaluations showed severe ketoacidosis. This is the first report of ketoacidosis caused by a SGLT2 inhibitor. It is necessary to not only pay attention when using a SGLT2 inhibitor in patients following a low-carbohydrate diet, but also to start a low-carbohydrate diet in patients treated with a SGLT2 inhibitor because of a high risk for developing ketoacidosis.

引用

页码：587 / 590

页数：4

共 9 条

[1] Efficacy and safety of low-carbohydrate diets - A systematic review
Bravata, DM
Sanders, L
Huang, J
Krumholz, HM
Olkin, I
Gardner, CD
Bravata, DM
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (14): : 1837 - 1850
[2] A life-threatening complication of Atkins diet
Chen, TY
Smith, W
Rosenstock, JL
Lessnau, KD
[J]. LANCET, 2006, 367 (9514) : 958 - 958
[3] Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action
Fujita, Yoshihito
Inagaki, Nobuya
[J]. JOURNAL OF DIABETES INVESTIGATION, 2014, 5 (03) : 265 - 275
[4] Management of hyperglycemic crises in patients with diabetes
Kitabchi, AE
Umpierrez, GE
Murphy, MB
Barrett, EJ
Kreisberg, RA
Malone, JI
Wall, BM
[J]. DIABETES CARE, 2001, 24 (01) : 131 - 153
[5] Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, Aurora
Solis-Herrera, Carolina
Daniele, Giuseppe
Eldor, Roy
Fiorentino, Teresa Vanessa
Tripathy, Devjit
Xiong, Juan
Perez, Zandra
Norton, Luke
Abdul-Ghani, Muhammad A.
DeFronzo, Ralph A.
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (02) : 509 - 514
[6] Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin
Mudaliar, Sunder
Henry, Robert R.
Boden, Guenther
Smith, Steven
Chalamandaris, Alexandros-Georgios
Duchesne, Dominique
Iqbal, Nayyar
List, James
[J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 (03) : 137 - 144
[7] Luseogliflozin for the treatment of type 2 diabetes
Seino, Yutaka
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (18) : 2741 - 2749
[8] Ketoacidosis during a low-carbohydrate diet
Shah, P
Isley, WL
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) : 97 - 98
[9] Analysis and a long-term follow up of ketosis-onset Japanese NIDDM patients
Tanaka, K
Moriya, T
Kanamori, A
Yajima, Y
[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 1999, 44 (02) : 137 - 146

← 1 →